GlassScriptPhysician profile
John C Mcclish
NPI 1427019249
$13,070.42
in general payments reported to CMS, 2019-2025
29 companies · $700 in 2025
The $700 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,898 · 2020: $3,699 · 2021: $827 · 2022: $1,026 · 2023: $3,029 · 2024: $893 · 2025: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,270 · Travel and Lodging: $1,352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,269.96 |
| Travel and Lodging | $1,351.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $3,381.09 | 2019-2023 | Diamondback Coronary |
| Inari Medical, INC. | $2,615.84 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Edwards Lifesciences Corporation | $1,330.00 | 2019-2025 | Sapien 3 Ultra Resilia |
| Medtronic Vascular, INC. | $888.85 | 2020 | |
| Abbott Laboratories | $641.42 | 2019-2025 | Cardiomems, Diamondback Coronary, Esprit |
| Shockwave Medical, INC | $574.89 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $427.69 | 2022-2025 | Corevalve Evolut R, Micra, Linq II |
| Heartflow, INC. | $381.78 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $349.07 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $325.99 | 2019-2022 | |
| Abiomed | $308.05 | 2020-2023 | Impella |
| Philips North America LLC | $251.68 | 2021-2025 | Peripheral Vascular Undivided |
| Pfizer INC. | $218.67 | 2019-2022 | |
| Stryker Corporation | $218.18 | 2025 | Artix Mt, Venacore Thrombectomy Catheter, Clottriever Bold Catheter |
| W. L. Gore & Associates, INC. | $165.31 | 2019-2024 | Gore Viabahn Vbx Balloon Expandable Endo, Excluder Conformable Aaa Endoprosthesis With Active Control |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $145.87 | 2024 | Carto 3 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $142.47 | 2019-2025 | Lifevest |
| Bard Peripheral Vascular, INC. | $129.95 | 2021 | |
| Amgen INC. | $98.21 | 2019-2022 | |
| Chiesi USA, INC. | $90.91 | 2022 | |
| Novartis Pharmaceuticals Corporation | $80.61 | 2019-2024 | |
| Cardiva Medical, INC. | $73.03 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs |
| E.R. Squibb & Sons, L.L.C. | $55.35 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $50.31 | 2019 | |
| Angiodynamics, INC. | $33.36 | 2019 | |
| Merit Medical Systems INC | $28.05 | 2020 | |
| Irhythm Technologies, INC. | $25.36 | 2022-2023 | Zio Xt Patch |
| Boston Scientific Corporation | $22.60 | 2025 | Eluvia |
| Altathera Pharmaceuticals LLC | $15.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mcclish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.